Replies to post #617 on Bristol Myers Squibb (BMY)

[Johnny_C]

Correction...GILD could still be in the running for BMY. On the call they stated they are still looking for more deals and have plenty of cash.. KITE is Biotech so not really much to integrate. It was a small deal for GILD anyway, 11 bil

[DewDiligence]

Nitpick: The GILD-KITE buyout premium was 29% (not 37%).